Colossal Biosciences Achieves Decacorn Status with $200M Series C Funding
Colossal Biosciences, the trailblazer in de-extinction technology, has secured an impressive $200 million in Series C funding, propelling its valuation to decacorn status at $10.2 billion. Founded in 2021, the company leverages CRISPR gene editing to revive extinct species like the woolly mammoth and dodo. With total funding reaching $435 million, Colossal aims to further advance its genetic engineering technologies, with promising applications in conservation, healthcare, and evolutionary biology.
Jan 17